Additional corroborating studies havebeen reported since, and clinical trials have begun testing this orsimilar TGFβ inhibition-based immuno-oncology strategies ina range of cancer types.6,7 Furthermore, TGFβblockade could also be useful to treat additional diseases where thiscytokine plays a role, such as fibrosis in vital organs like the lung,liver, kidney, and skin.11,12. The gene discussed is TGFB1; the disease is cancer.